Cardiovascular Journal of Africa: Vol 25 No 5 (September/October 2014)

CARDIOVASCULAR JOURNAL OF AFRICA • Volume 25, No 5, September/October 2014

216

AFRICA

References

World Health Organization (WHO). The top ten causes of death. Fact

sheet No 310/2008.

Zimmerman BJ, Granger DN. Reperfusion injury.

Surg Clin North Am

1992;

: 65

–

83.

Verma S, Fedak PW, Weisel RD,

et al

. Fundamentals of reperfusion

injury for the clinical cardiologist.

Circulation

2002;

105

: 1332

–

1336.

Chatterjee A, Black SM, Catravas JD. Endothelial nitric oxide (NO) and

its pathophysiologic regulation.

Vascul Pharmacol

2008;

: 134

–

140.

Sydow K, Münzel T. ADMA and oxidative stress.

Atherosclerosis

2003;

: 41

–

51.

Hori T, Matsubara T, Ishibashi T,

et al.

Significance of asymmetric

dimethylarginine (ADMA) concentrations during coronary circulation

in patients with vazospastic angina

. Circ J

2003;

: 305

–

311.

Griendling KK, Sorescu D, Ushio-Fukai M. NAD(P)H oxidase: role in

cardiovascular biology and disease.

Circ Res

2000;

: 494

–

501.

Pignatelli P, Carnevale R, Di Santo S,

et al

. Rosuvastatin reduces

platelet recruitment by inhibiting NADPH oxidase activation.

Biochem

Pharmacol

2012;

84:

1635–1642.

Bao W, Hu E, Tao L et al. Inhibition of rho-kinase protects the heart

against ischemia/reperfusion injury.

Cardiovasc Res

2004;

: 548-558.

10. Liu CC, Huang Y, Zhang J,

et al

. Effect of carvedilol on cardiac dysfunc-

tion 4 days after myocardial infarction in rats: role of toll-like receptor

4 and

-arrestin 2.

Eur Rev Med Pharmacol Sci

2013;

: 2103

–

2110.

11. Mount PF, Kemp BE, Power DA. Regulation of endothelial and

myocardial NO synthesis by multi-site eNOS phosphorylation.

J Mol

Cell Cardiol

2007;

: 271

–

279.

12. Pritchard KA, Jr, Ackerman AW, Gross ER et al. Heat shock protein

90 mediates the balance of nitric oxide and superoxide anion from

endothelial nitric-oxide synthase.

J Biol Chem

2001;

276

: 17621

–

17624.

13. Garcia-Cardena G, Fan R, Shah V,

et al

. Dynamic activation of

endothelial nitric oxide synthase by Hsp90.

Nature

1998;

392

: 821

–

824.

14. Young LH, Ikeda Y, Lefer AM. Caveolin-1 peptide exerts cardioprotec-

tive effects in myocardial ischemia-reperfusion via nitric oxide mecha-

nism.

Am J Physiol Heart Circ Physiol

2001;

280

: 2489

–

2495.

15. Jasmin JF, Rengo G, Lymperopoulos A et al. Caveolin-1 deficiency

exacerbates cardiac dysfunction and reduces survival in mice with

myocardial infarction.

Am J Physiol Heart Circ Physiol

2011;

300

1274

–

1281.

16. Suh JW, Choi DJ, Chang HJ,

et al

. HMG-CoA reductase inhibitor

improves endothelial dysfunction in spontaneous hypertensive rats via

down-regulation of caveolin-1 and activation of endothelial nitric oxide

synthase.

J Korean Med Sci

2010;

: 16

–

23.

17. Mahalwar R, Khanna D. Pleiotropic antioxidant potential of rosuv-

astatin in preventing cardiovascular disorders.

Eur J Pharmacol

2013;

711

: 57

–

62.

18. Liuni A, Luca MC, Gori T,

et al

. The endothelial-protective effects of

HMG-CoA reductase inhibition in the setting of ischemia and reperfu-

sion injury.

Clin Hemorheol Microcirc

2010;

: 161

–

167.

19. Lu TM, Ding YA, Leu HB,

et al.

Effect of rosuvastatin on plasma levels

of asymmetric dimethylarginine in patients with hypercholesterolemia.

Am J Cardiol

2004;

: 157

–

161.

20. Pelat M, Dessy C, Massion P,

et al

. Rosuvastatin decreases caveolin-1

and improves nitric oxide-dependent heart rate and blood pressure

variability in apolipoprotein E-/- mice

in vivo

Circulation

2003;

107

2480

–

2486.

21. Uekawa K, Hasegawa Y, Ma M,

et al

. Rosuvastatin ameliorates early

brain injury after subarachnoid hemorrhage via suppression of super-

oxide formation and nuclear factor-kappa B activation in rats.

J Stroke

Cerebrovasc Dis

2014; S1052

–

3057(13)00508-9.

22. Patti G, Cannon CP, Murphy SA,

et al.

Clinical benefit of statin

pretreatment in patients undergoing percutaneous coronary interven-

tion: a collaborative patient-level meta-analysis of randomized studies.

Circulation

2011;

123

: 1622–1632.

23. Ke D, Fang J, Fan L,

et al

. Regulatory T cells contribute to rosuvastatin-

induced cardioprotection against ischemia-reperfusion injury

Coron

Artery Dis

2013;

: 334

–

341.

24. Kuhn EW, Liakopoulos OJ, Deppe AC,

et al.

Rosuvastatin reloading

before cardiac surgery with cardiopulmonary bypass.

Eur Surg Res

2013;

: 1

–

13.

25. Ma M, Uekawa K, Hasegawa Y,

et al

. Pretreatment with rosuvasta-

tin protects against focal cerebral ischemia/reperfusion injury in rats

through attenuation of oxidative stress and inflammation.

Brain Res

2013;

1519

: 87

–

94.

26. Rochette L, Lorin J, Zeller M,

et al

. Nitric oxide synthase inhibition and

oxidative stress in cardiovascular diseases: possible therapeutic targets?

Pharmacol Ther

2013;

140

: 239

–

257.

27. Endemann DH, Schiffrin E. Endothelial dysfunction.

J Am Soc Nephrol

2004;

: 1983

–

1992.

28. Böger RH. Asymmetric dimethyl arginine (ADMA) and cardiovascular

disease: insights from prospective clinical trials.

Vasc Med

2005;

–

25.

29. Coskun C, Avci B, Yalcin M,

et al

. Protective effect of CDP-choline on

ischemia-reperfusion-induced myocardial tissue injury in rats.

Ir J Med

Sci

2013 [Epub ahead of print].

30. Stühlinger MC, Conci E, Haubner BJ,

et al

. Asymmetric dimethyl

L-arginine (ADMA) is a critical regulator of myocardial reperfusion

injury.

Cardiovasc Res

2007;

: 417

–

425.

31. Budas GR, Churchill EN, Disatnik MH,

et al

. Mitochondrial import

of PKC epsilon is mediated by HSP90: a role in cardioprotection from

ischaemia and reperfusion injury.

Cardiovasc Res

2010;

: 83

–

92.

32. Kalmar B, Greensmith L. Induction of heat shock proteins for protec-

tion against oxidative stress.

Adv Drug Deliv Rev

2009;

: 310

–

318.

33. Bao W, Hu E, Tao L,

et al

. Inhibition of rho-kinase protects the heart

against ischemia/reperfusion injury.

Cardiovasc Res

2004;

: 548

–

58.

34. Rawlings R, Nohria A, Liu PY,

et al

. Comparison of effects of rosu-

vastatin (10 mg) versus atorvastatin (40 mg) on rhokinase activity in

caucasian men with a previous atherosclerotic event.

Am J Cardiol

2009;

103

: 437

–

441.

35. Li X, Yang G, Zhao G,

et al.

Rosuvastatin attenuates the elevation in

blood pressure induced by overexpression of human C-reactive protein.

Hypertens Res

2011;

: 869

–

875.

36. Sun X, Tong H, Zhang M,

et al

. Rosuvastatin inhibits the smooth

muscle cell proliferation by targeting TNF

mediated Rho kinase path-

way

. J Geriatr Cardiol

2012;

: 180

–

184.

37. Ha T, Liu L, Kelley J,

et al.

Toll-like receptors: new players in myocardial

ischemia/reperfusion injury.

Antioxid Redox Signal

2011;

: 1875

–

1893.

38. Pye J, Ardeshirpour F, McCain A,

et al

. Proteasome inhibition ablates

activation of NF-kappa B in myocardial reperfusion and reduces reper-

fusion injury.

Am J Physiol Heart Circ Physiol

2003;

284

: 919

–9

26.